Litcius/Paper detail

The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant

Mehul S. Suthar, Kelly E. Manning, Madison L Ellis, Shilpi Jain, Kareem Bechnak, Jake Vander Velden, Farida Laboune, Amy R. Henry, Sucheta Godbole, Sung Jin Kim, Malaya K. Sahoo, Isabel Paredes, Serena Maria Dib, Suha Kalash, Christelle Radi, Heather Hicks, Azaibi Tamin, Meredith E. Davis-Gardner, Nicole E. Bowen, Peter W. Cook, Clinton R. Paden, Jennifer L. Harcourt, Benjamin A. Pinsky, Daniel C. Douek, Nadine Rouphael, Alberto Moreno

2025The Lancet Infectious Diseases14 citationsDOI

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineInternal medicineOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchImmunodeficiency and Autoimmune DisordersBlood groups and transfusion
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant | Litcius